FY2025 · ended Dec 31, 2025 · Revenue $16.31B, +5.9% YoY · Filed Feb 17, 2026
Iqvia Holdings Inc. (IQV) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $16.3 billion and net income of $1.4 billion. Free cash flow was $2.1 billion. As of Sep 30, 2026 it held $2.4 billion in cash and investments and $16.3 billion in total debt.
Revenue (TTM)
$17.31B
+8.8% vs year-ago TTM
Net income (TTM)
$1.39B
+8.7% vs year-ago TTM
Operating cash flow (TTM)
$2.74B
-2.4% vs year-ago TTM
Free cash flow (TTM)
$2.08B
-6.0% vs year-ago TTM
EPS (TTM)
$8.25
+13.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
169.70M
-3.6% vs prior year
Net cash
$-13.89B
as of Sep 30, 2026
Operating margin
12.8%
FY 2026
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- IQV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1478242
- Former names
- Quintiles IMS Holdings, Inc. (until Nov 3, 2017); Quintiles Transnational Holdings Inc. (until Sep 22, 2016)
Other Services-Commercial Physical & Biological Research companies
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $16.3B | $15.4B | $15.0B | $14.4B | $13.9B |
| Operating income | $2.2B | $2.2B | $2.0B | $1.8B | $1.4B |
| Net income | $1.4B | $1.4B | $1.4B | $1.1B | $966.0M |
| Diluted EPS | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 |
| Operating cash flow | $2.7B | $2.7B | $2.1B | $2.3B | $2.9B |
| Free cash flow | $2.1B | $2.1B | $1.5B | $1.6B | $2.3B |
| Total assets | $29.9B | $26.9B | $26.7B | $25.3B | $24.7B |
| Total liabilities | $23.3B | $20.8B | $20.6B | $19.6B | $18.6B |
| Stockholders' equity | $6.5B | — | — | — | $6.0B |
| Cash and investments | $2.1B | $1.8B | $1.5B | $1.3B | $1.5B |
| Total debt | $16.3B | $14.5B | $14.2B | $13.4B | $12.8B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 27, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Jul 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 28, 2026 | Jul 28, 2026 |
All 1000 Iqvia Holdings Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.